Ataibeckley Inc. (ATAI) — SEC Filings
Ataibeckley Inc. (ATAI) — 50 SEC filings. Latest: 4 (Apr 22, 2026). Includes 31 8-K, 6 10-Q, 3 DEFA14A.
View Ataibeckley Inc. on SEC EDGAR
Overview
Ataibeckley Inc. (ATAI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 5, 2025: Atai Beckley N.V. filed an 8-K on December 5, 2025, reporting other events and financial statements. The company, previously known as ATAI Life Sciences N.V., is incorporated in The Netherlands and operates in the Pharmaceutical Preparations sector.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 1 bearish, 48 neutral, 1 mixed. The dominant filing sentiment for Ataibeckley Inc. is neutral.
Filing Type Overview
Ataibeckley Inc. (ATAI) has filed 1 4, 31 8-K, 6 10-Q, 3 DEFA14A, 2 DEF 14A, 2 10-K, 1 10-Q/A, 3 SC 13D/A, 1 SC 13G/A with the SEC between Feb 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of ATAI's 46 recent filings, 1 were flagged as high-risk, 25 as medium-risk, and 20 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $3.023M |
| Net Income | -$115.309M |
| EPS | N/A |
| Debt-to-Equity | 0.50 |
| Cash Position | $30.402M |
| Operating Margin | N/A |
| Total Assets | $239.820M |
| Total Debt | $0M |
Key Executives
- Christian Angermayer
- Patrick Trucc
- Srinivas Rao
- Josef von Ferber
- Christopher Perez
- Dr. Srinivas Rao
- Dr. Jonathan Roth
- Ryan Barrett
- Dr. David Epstein
- Dr. Paul Berns
Industry Context
Atai Beckley N.V. operates in a dynamic biotechnology and pharmaceutical sector, characterized by high R&D investment and significant regulatory hurdles. The industry is competitive, with companies vying for market share through innovation and strategic partnerships. Trends include a growing focus on specialized therapeutic areas and the increasing importance of digital assets and services.
Top Tags
sec-filing (8) · material-agreement (7) · 8-K (5) · pharmaceuticals (5) · financials (5) · filing (4) · 8-k (4) · disclosure (4) · proxy-statement (4) · governance (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC File Number | 001-40493 | Identifies the company's filing history with the SEC. |
| Film Number | 251553645 | Internal SEC processing number for the filing. |
| Net Loss | $115.309M | Increased from $111.058M in 2024 for the nine months ended September 30. |
| Total Revenue | $3.023M | Significant increase from $313K in 2024 for the nine months ended September 30, driven by R&D services. |
| Change in Fair Value of Assets and Liabilities, Net | $45.100M | Major expense contributing to net loss, up from $33.764M in 2024. |
| Research and Development Expenses | $37.100M | Increased from $36.513M in 2024 for the nine months ended September 30, reflecting ongoing pipeline investment. |
| General and Administrative Expenses | $40.002M | Increased from $36.226M in 2024 for the nine months ended September 30. |
| Cash and Cash Equivalents | $30.402M | Increased from $17.505M at December 31, 2024, indicating successful capital raises. |
| Common Shares Outstanding | 363,190,522 | As of November 10, 2025, reflecting share issuances. |
| Additional Paid-in Capital from Share Issuance | $59.117M | Resulted from issuing 30,119,048 common shares, net of costs, for the nine months ended September 30, 2025. |
| Commission File Number | 001-40493 | Identifies the SEC filing for ATAI Life Sciences N.V. |
| Net Loss (Q2 2025) | $27.7M | Decreased from $57.3M in Q2 2024, indicating improved financial performance. |
| Net Loss (H1 2025) | $54.2M | Decreased from $84.7M in H1 2024, showing a reduced burn rate. |
| Cash & Cash Equivalents | $61.9M | Increased significantly from $17.5M at Dec 31, 2024, bolstering liquidity. |
| Total Revenue (Q2 2025) | $719K | Increased from $273K in Q2 2024, primarily from R&D services. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Ataibeckley Inc. (ATAI)?
Ataibeckley Inc. has 50 recent SEC filings from Feb 2024 to Apr 2026, including 31 8-K, 6 10-Q, 3 DEFA14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ATAI filings?
Across 50 filings, the sentiment breakdown is: 1 bearish, 48 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Ataibeckley Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Ataibeckley Inc. (ATAI) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Ataibeckley Inc.?
Key financial highlights from Ataibeckley Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ATAI?
The investment thesis for ATAI includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Ataibeckley Inc.?
Key executives identified across Ataibeckley Inc.'s filings include Christian Angermayer, Patrick Trucc, Srinivas Rao, Josef von Ferber, Christopher Perez and 5 others.
What are the main risk factors for Ataibeckley Inc. stock?
Of ATAI's 46 assessed filings, 1 were flagged high-risk, 25 medium-risk, and 20 low-risk.
What are recent predictions and forward guidance from Ataibeckley Inc.?
Forward guidance and predictions for Ataibeckley Inc. are extracted from SEC filings as they are enriched.